President Donald Trump announced a significant agreement on Thursday, November 6, with pharmaceutical companies Eli Lilly and Novo Nordisk aimed at reducing the prices of their popular weight-loss medications.
The deal also includes expanded Medicare coverage for these drugs, making them more accessible to older adults who rely on the program.
Under the negotiated agreement, both Medicare and Medicaid will begin covering Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. This move is expected to ease the financial burden on patients who need these treatments.
In addition to insurance coverage, consumers will have the option to purchase these medications at discounted rates through the federal government’s direct-to-consumer platform, TrumpRx. This website is scheduled to launch in 2026, further enhancing affordability and access.
This initiative represents a step forward in making effective weight-loss drugs more attainable for a broader population, particularly seniors.
https://www.allsides.com/news/2025-11-06-0800/healthcare-trump-announces-lower-prices-medicare-coverage-popular-weight-loss-drugs